Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells

NEXT STORY
Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine
PREV STORY
Silencil Reviews: Trustworthy Ingredients or Tinnitus Relief Complaints? by 2021 Review.com
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017

Acceptable tolerability observed in first-in-human study Encouraging initial anti-leukemic activity observed in relapsed/refractory AML ...

author_avatar
NASDAQ Market News

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

author_avatar
NASDAQ Market News

Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement                                                                                                                   No. 12/2018                                                                                                                                        Company Registration No. 32266355                                                                                                                                                                                              Arimoclomol was well-tolerated in patients ...

author_avatar
NASDAQ Market News